<DOC>
	<DOC>NCT00612599</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 50 three times a day to biphasic insulin aspart 70 three times a day in non-obese and obese with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes for at least 12 months Stable glycaemic control, having been on the existing treatment for at least 1 month BMI between 2328 kg/m2 (nonobese) or between 3035 kg/m2 (obese) HbA1c below 9.0% Willing to eat three main meals per day during the trial period and perform SelfMonitoring of Blood Glucose (SBGM) regularly A history of drug abuse or alcohol dependence Blood donation within the last 3 months Currently being treated with systemic corticosteroids, Mono Amine Oxidase (MAO) inhibitors, betaadrenergic blocking agents, anabolic steroids or any other drug affecting blood glucose Severe, uncontrolled hypertension Proliferative retinopathy or maculopathy requiring acute treatment Pregnancy, breastfeeding, intention of becoming pregnant or judged not to be using adequate contraceptive measures (for women of childbearing potential only contraceptive pills and intra uterine devices are considered as adequate contraceptive methods)</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>